Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...
Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography–Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal ...
Intravenous drip Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma. Combination avelumab and axitinib has shown ...
Findings from the LITESPARK-005 trial showed a statistically significant improvement in progression free survival with belzutifan compared with everolimus. The Food and Drug Administration (FDA) has ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results